Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

No association between ATP-binding cassette transporter G2 rs2231142 (Q141K) and urate-lowering response to febuxostat.

Stamp LK, Topless R, Miner JN, Dalbeth N, Merriman T.

Rheumatology (Oxford). 2018 Dec 27. doi: 10.1093/rheumatology/key423. [Epub ahead of print] No abstract available.

PMID:
30597115
2.

Characterization of Stereoselective Metabolism, Inhibitory Effect on Uric Acid Uptake Transporters, and Pharmacokinetics of Lesinurad Atropisomers.

Yang C, Zhou D, Shen Z, Wilson DM, Renner M, Miner JN, Girardet JL, Lee CA.

Drug Metab Dispos. 2019 Feb;47(2):104-113. doi: 10.1124/dmd.118.080549. Epub 2018 Nov 15.

PMID:
30442650
3.

ABCG2 rs2231142 (Q141K) and oxypurinol concentrations in people with gout receiving allopurinol.

Stamp LK, Wallace M, Roberts RL, Frampton C, Miner JN, Merriman TR, Dalbeth N.

Drug Metab Pharmacokinet. 2018 Dec;33(6):241-242. doi: 10.1016/j.dmpk.2018.09.002. Epub 2018 Sep 18. No abstract available.

PMID:
30274827
4.

The relationship between ferritin and urate levels and risk of gout.

Fatima T, McKinney C, Major TJ, Stamp LK, Dalbeth N, Iverson C, Merriman TR, Miner JN.

Arthritis Res Ther. 2018 Aug 15;20(1):179. doi: 10.1186/s13075-018-1668-y.

5.

Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy Japanese and non-Asian male subjects.

Hall J, Gillen M, Liu S, Miner JN, Valdez S, Shen Z, Lee C.

Drug Des Devel Ther. 2018 Jun 20;12:1799-1807. doi: 10.2147/DDDT.S152659. eCollection 2018.

6.

Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Allopurinol in Adult Male Subjects With Gout.

Kankam M, Hall J, Gillen M, Yang X, Shen Z, Lee C, Liu S, Miner JN, Walker S, Clauson V, Wilson D, Nguyen M.

J Clin Pharmacol. 2018 Sep;58(9):1214-1222. doi: 10.1002/jcph.1119. Epub 2018 May 7.

7.

Accuracy of the HumaSensplus point-of-care uric acid meter using capillary blood obtained by fingertip puncture.

Fabre S, Clerson P, Launay JM, Gautier JF, Vidal-Trecan T, Riveline JP, Platt A, Abrahamsson A, Miner JN, Hughes G, Richette P, Bardin T.

Arthritis Res Ther. 2018 May 2;20(1):78. doi: 10.1186/s13075-018-1585-0.

8.

Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with febuxostat in adults with gout: a phase IIa, open-label study.

Fleischmann R, Winkle P, Hall J, Valdez S, Liu S, Yan X, Hicks L, Lee C, Miner JN, Gillen M, Hernandez-Illas M.

RMD Open. 2018 Apr 9;4(1):e000647. doi: 10.1136/rmdopen-2018-000647. eCollection 2018.

9.

Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study.

Fleischmann R, Winkle P, Miner JN, Yan X, Hicks L, Valdez S, Hall J, Liu S, Shen Z, Gillen M, Hernandez-Illas M.

RMD Open. 2018 Feb 8;4(1):e000584. doi: 10.1136/rmdopen-2017-000584. eCollection 2018.

10.

Omega-3-carboxylic acids provide efficacious anti-inflammatory activity in models of crystal-mediated inflammation.

Iverson C, Bacong A, Liu S, Baumgartner S, Lundström T, Oscarsson J, Miner JN.

Sci Rep. 2018 Jan 19;8(1):1217. doi: 10.1038/s41598-018-19252-x.

11.

Association between ABCG2 rs2231142 and poor response to allopurinol: replication and meta-analysis.

Wallace MC, Roberts RL, Nanavati P, Miner JN, Dalbeth N, Topless R, Merriman TR, Stamp LK.

Rheumatology (Oxford). 2018 Apr 1;57(4):656-660. doi: 10.1093/rheumatology/kex467. Review.

PMID:
29342288
12.

Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy adult male subjects.

Shen Z, Gillen M, Miner JN, Bucci G, Wilson DM, Hall JW.

Drug Des Devel Ther. 2017 Jul 7;11:2077-2086. doi: 10.2147/DDDT.S140658. eCollection 2017.

13.

Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout.

Tan PK, Liu S, Gunic E, Miner JN.

Sci Rep. 2017 Apr 6;7(1):665. doi: 10.1038/s41598-017-00706-7.

14.

Plasma oxypurinol as a measure of adherence in clinical trials.

Stamp LK, Merriman T, Frampton C, Zhang M, Wallace M, Miner JN, Dalbeth N.

Ann Rheum Dis. 2018 Feb;77(2):313-314. doi: 10.1136/annrheumdis-2016-210661. Epub 2017 Jan 5. No abstract available.

PMID:
28057666
15.

A Therapeutic Uricase with Reduced Immunogenicity Risk and Improved Development Properties.

Nyborg AC, Ward C, Zacco A, Chacko B, Grinberg L, Geoghegan JC, Bean R, Wendeler M, Bartnik F, O'Connor E, Gruia F, Iyer V, Feng H, Roy V, Berge M, Miner JN, Wilson DM, Zhou D, Nicholson S, Wilker C, Wu CY, Wilson S, Jermutus L, Wu H, Owen DA, Osbourn J, Coats S, Baca M.

PLoS One. 2016 Dec 21;11(12):e0167935. doi: 10.1371/journal.pone.0167935. eCollection 2016.

16.

Erratum to: Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney.

Miner JN, Tan PK, Hyndman D, Liu S, Iverson C, Nanavati P, Hagerty DT, Manhard K, Shen Z, Girardet JL, Yeh LT, Terkeltaub R, Quart B.

Arthritis Res Ther. 2016 Oct 12;18(1):236. No abstract available.

17.

Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney.

Miner JN, Tan PK, Hyndman D, Liu S, Iverson C, Nanavati P, Hagerty DT, Manhard K, Shen Z, Girardet JL, Yeh LT, Terkeltaub R, Quart B.

Arthritis Res Ther. 2016 Oct 3;18(1):214. Erratum in: Arthritis Res Ther. 2016 Oct 12;18(1):236.

18.

Mechanism of high affinity inhibition of the human urate transporter URAT1.

Tan PK, Ostertag TM, Miner JN.

Sci Rep. 2016 Oct 7;6:34995. doi: 10.1038/srep34995.

19.

Coevolution of URAT1 and Uricase during Primate Evolution: Implications for Serum Urate Homeostasis and Gout.

Tan PK, Farrar JE, Gaucher EA, Miner JN.

Mol Biol Evol. 2016 Sep;33(9):2193-200. doi: 10.1093/molbev/msw116. Epub 2016 Jun 26.

20.

Patients with gout differ from healthy subjects in renal response to changes in serum uric acid.

Liu S, Perez-Ruiz F, Miner JN.

Joint Bone Spine. 2017 Mar;84(2):183-188. doi: 10.1016/j.jbspin.2016.04.007. Epub 2016 Jun 17.

PMID:
27324603
21.

Urate Handling in the Human Body.

Hyndman D, Liu S, Miner JN.

Curr Rheumatol Rep. 2016 Jun;18(6):34. doi: 10.1007/s11926-016-0587-7. Review.

22.

Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol.

Perez-Ruiz F, Sundy JS, Miner JN, Cravets M, Storgard C; RDEA594-203 Study Group.

Ann Rheum Dis. 2016 Jun;75(6):1074-80. doi: 10.1136/annrheumdis-2015-207919. Epub 2016 Jan 7.

23.

An analytical comparison between point-of-care uric acid testing meters.

Paraskos J, Berke Z, Cook J, Miner JN, Braddock M, Platt A, Hughes G.

Expert Rev Mol Diagn. 2016;16(3):373-82. doi: 10.1586/14737159.2016.1134326. Epub 2016 Jan 11.

PMID:
26689648
24.

A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer.

Adjei AA, Richards DA, El-Khoueiry A, Braiteh F, Becerra CH, Stephenson JJ Jr, Hezel AF, Sherman M, Garbo L, Leffingwell DP, Iverson C, Miner JN, Shen Z, Yeh LT, Gunawan S, Wilson DM, Manhard KJ, Rajagopalan P, Krissel H, Clendeninn NJ.

Clin Cancer Res. 2016 May 15;22(10):2368-76. doi: 10.1158/1078-0432.CCR-15-1681. Epub 2015 Dec 7.

25.

Xanthine oxidoreductase regulates macrophage IL1β secretion upon NLRP3 inflammasome activation.

Ives A, Nomura J, Martinon F, Roger T, LeRoy D, Miner JN, Simon G, Busso N, So A.

Nat Commun. 2015 Mar 24;6:6555. doi: 10.1038/ncomms7555.

26.

Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia.

Fleischmann R, Kerr B, Yeh LT, Suster M, Shen Z, Polvent E, Hingorani V, Quart B, Manhard K, Miner JN, Baumgartner S; RDEA594-111 Study Group.

Rheumatology (Oxford). 2014 Dec;53(12):2167-74. doi: 10.1093/rheumatology/ket487. Epub 2014 Feb 8.

PMID:
24509406
27.

Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma.

Schmieder R, Puehler F, Neuhaus R, Kissel M, Adjei AA, Miner JN, Mumberg D, Ziegelbauer K, Scholz A.

Neoplasia. 2013 Oct;15(10):1161-71.

28.

Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.

Weekes CD, Von Hoff DD, Adjei AA, Leffingwell DP, Eckhardt SG, Gore L, Lewis KD, Weiss GJ, Ramanathan RK, Dy GK, Ma WW, Sheedy B, Iverson C, Miner JN, Shen Z, Yeh LT, Dubowy RL, Jeffers M, Rajagopalan P, Clendeninn NJ.

Clin Cancer Res. 2013 Mar 1;19(5):1232-43. doi: 10.1158/1078-0432.CCR-12-3529. Epub 2013 Feb 22.

29.

Discovery of orally available tetrahydroquinoline-based glucocorticoid receptor agonists.

Hudson AR, Higuchi RI, Roach SL, Adams ME, Vassar A, Syka PM, Mais DE, Miner JN, Marschke KB, Zhi L.

Bioorg Med Chem Lett. 2011 Mar 15;21(6):1697-700. doi: 10.1016/j.bmcl.2011.01.093. Epub 2011 Jan 26.

PMID:
21316964
30.

Novel mitogen-activated protein kinase kinase inhibitors.

Chapman MS, Miner JN.

Expert Opin Investig Drugs. 2011 Feb;20(2):209-20. doi: 10.1517/13543784.2011.548803. Review.

PMID:
21235429
31.

Tetrahydroquinoline glucocorticoid receptor agonists: discovery of a 3-hydroxyl for improving receptor selectivity.

Roach SL, Higuchi RI, Hudson AR, Adams ME, Syka PM, Mais DE, Miner JN, Marschke KB, Zhi L.

Bioorg Med Chem Lett. 2011 Jan 1;21(1):168-71. doi: 10.1016/j.bmcl.2010.11.047. Epub 2010 Nov 11.

PMID:
21115247
32.

Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts.

Chang Q, Chapman MS, Miner JN, Hedley DW.

BMC Cancer. 2010 Sep 28;10:515. doi: 10.1186/1471-2407-10-515.

33.

RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer.

Iverson C, Larson G, Lai C, Yeh LT, Dadson C, Weingarten P, Appleby T, Vo T, Maderna A, Vernier JM, Hamatake R, Miner JN, Quart B.

Cancer Res. 2009 Sep 1;69(17):6839-47. doi: 10.1158/0008-5472.CAN-09-0679. Epub 2009 Aug 25.

34.

Sexual differentiation of the spinal nucleus of the bulbocavernosus is not mediated solely by androgen receptors in muscle fibers.

Niel L, Shah AH, Lewis GA, Mo K, Chatterjee D, Fernando SM, Hong MH, Chang WY, Vollmayr P, Rosen J, Miner JN, Monks DA.

Endocrinology. 2009 Jul;150(7):3207-13. doi: 10.1210/en.2008-1478. Epub 2009 Mar 12.

35.

Discovery of nonsteroidal glucocorticoid receptor ligands based on 6-indole-1,2,3,4-tetrahydroquinolines.

Roach SL, Higuchi RI, Adams ME, Liu Y, Karanewsky DS, Marschke KB, Mais DE, Miner JN, Zhi L.

Bioorg Med Chem Lett. 2008 Jun 15;18(12):3504-8. doi: 10.1016/j.bmcl.2008.05.029. Epub 2008 May 11.

PMID:
18513967
36.

LGD-5552, an antiinflammatory glucocorticoid receptor ligand with reduced side effects, in vivo.

López FJ, Ardecky RJ, Bebo B, Benbatoul K, De Grandpre L, Liu S, Leibowitz MD, Marschke K, Rosen J, Rungta D, Viveros HO, Yen WC, Zhi L, Negro-Vilar A, Miner JN.

Endocrinology. 2008 May;149(5):2080-9. doi: 10.1210/en.2007-1353. Epub 2008 Jan 24.

PMID:
18218700
37.

Cell-specific activation of the human skeletal alpha-actin by androgens.

Hong MH, Sun H, Jin CH, Chapman M, Hu J, Chang W, Burnett K, Rosen J, Negro-Vilar A, Miner JN.

Endocrinology. 2008 Mar;149(3):1103-12. Epub 2007 Dec 6.

PMID:
18063690
38.

Antiinflammatory glucocorticoid receptor ligand with reduced side effects exhibits an altered protein-protein interaction profile.

Miner JN, Ardecky B, Benbatoul K, Griffiths K, Larson CJ, Mais DE, Marschke K, Rosen J, Vajda E, Zhi L, Negro-Vilar A.

Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19244-9. Epub 2007 Nov 21.

39.

Synthesis and characterization of nonsteroidal glucocorticoid receptor modulators for multiple myeloma.

Hudson AR, Roach SL, Higuchi RI, Phillips DP, Bissonnette RP, Lamph WW, Yen J, Li Y, Adams ME, Valdez LJ, Vassar A, Cuervo C, Kallel EA, Gharbaoui CJ, Mais DE, Miner JN, Marschke KB, Rungta D, Negro-Vilar A, Zhi L.

J Med Chem. 2007 Sep 20;50(19):4699-709. Epub 2007 Aug 17.

PMID:
17705362
40.

5(Z)-benzylidene-1,2-dihydro-9-hydroxy-10-methoxy-2,2,4-trimethyl-5H-1-aza-6-oxa-chrysenes as non-steroidal glucocorticoid receptor modulators.

Ardecky RJ, Hudson AR, Phillips DP, Tyhonas JS, Deckhut C, Lau TL, Li Y, Martinborough EA, Roach SL, Higuchi RI, Lopez FJ, Marschke KB, Miner JN, Karanewsky DS, Negro-Vilar A, Zhi L.

Bioorg Med Chem Lett. 2007 Aug 1;17(15):4158-62. Epub 2007 May 23.

PMID:
17553679
41.

The growth plate sparing effects of the selective glucocorticoid receptor modulator, AL-438.

Owen HC, Miner JN, Ahmed SF, Farquharson C.

Mol Cell Endocrinol. 2007 Jan 29;264(1-2):164-70. Epub 2006 Dec 19.

PMID:
17182172
42.

Structure of the ligand-binding domain (LBD) of human androgen receptor in complex with a selective modulator LGD2226.

Wang F, Liu XQ, Li H, Liang KN, Miner JN, Hong M, Kallel EA, van Oeveren A, Zhi L, Jiang T.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2006 Nov 1;62(Pt 11):1067-71. Epub 2006 Oct 25.

43.

An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate.

Miner JN, Chang W, Chapman MS, Finn PD, Hong MH, López FJ, Marschke KB, Rosen J, Schrader W, Turner R, van Oeveren A, Viveros H, Zhi L, Negro-Vilar A.

Endocrinology. 2007 Jan;148(1):363-73. Epub 2006 Oct 5.

PMID:
17023534
44.

New and improved glucocorticoid receptor ligands.

Miner JN, Hong MH, Negro-Vilar A.

Expert Opin Investig Drugs. 2005 Dec;14(12):1527-45. Review.

PMID:
16307492
45.

The structural basis of androgen receptor activation: intramolecular and intermolecular amino-carboxy interactions.

Schaufele F, Carbonell X, Guerbadot M, Borngraeber S, Chapman MS, Ma AA, Miner JN, Diamond MI.

Proc Natl Acad Sci U S A. 2005 Jul 12;102(28):9802-7. Epub 2005 Jul 1.

46.

The search for safer glucocorticoid receptor ligands.

Rosen J, Miner JN.

Endocr Rev. 2005 May;26(3):452-64. Epub 2005 Apr 6. Review.

PMID:
15814846
47.

Differentiation of in vitro transcriptional repression and activation profiles of selective glucocorticoid modulators.

Elmore SW, Pratt JK, Coghlan MJ, Mao Y, Green BE, Anderson DD, Stashko MA, Lin CW, Falls D, Nakane M, Miller L, Tyree CM, Miner JN, Lane B.

Bioorg Med Chem Lett. 2004 Apr 5;14(7):1721-7.

PMID:
15026058
48.

Nonsteroidal selective glucocorticoid modulators: the effect of C-10 substitution on receptor selectivity and functional potency of 5-allyl-2,5-dihydro-2,2,4-trimethyl-1H-[1]benzopyrano[3,4-f]quinolines.

Kym PR, Kort ME, Coghlan MJ, Moore JL, Tang R, Ratajczyk JD, Larson DP, Elmore SW, Pratt JK, Stashko MA, Falls HD, Lin CW, Nakane M, Miller L, Tyree CM, Miner JN, Jacobson PB, Wilcox DM, Nguyen P, Lane BC.

J Med Chem. 2003 Mar 13;46(6):1016-30.

PMID:
12620078
49.

A novel antiinflammatory maintains glucocorticoid efficacy with reduced side effects.

Coghlan MJ, Jacobson PB, Lane B, Nakane M, Lin CW, Elmore SW, Kym PR, Luly JR, Carter GW, Turner R, Tyree CM, Hu J, Elgort M, Rosen J, Miner JN.

Mol Endocrinol. 2003 May;17(5):860-9. Epub 2003 Feb 13.

PMID:
12586843
50.

A nonsteroidal glucocorticoid receptor antagonist.

Miner JN, Tyree C, Hu J, Berger E, Marschke K, Nakane M, Coghlan MJ, Clemm D, Lane B, Rosen J.

Mol Endocrinol. 2003 Jan;17(1):117-27.

PMID:
12511611

Supplemental Content

Loading ...
Support Center